AbbVie Presents Positive Clinical Data for IBD Treatments at ACG Meeting
What happened
AbbVie presented 22 scientific abstracts at the American College of Gastroenterology 2026 Annual Scientific Meeting. The presentations included new Phase 3 AFFIRM data showing higher rates of clinical and endoscopic response for SKYRIZI in advanced therapy-naïve Crohn's disease. Additionally, real-world studies highlighted that RINVOQ achieved disease control in advanced Crohn's disease patients.
From prnewswire.com
Why it matters
The presentation of positive clinical data for SKYRIZI and RINVOQ reinforces AbbVie's market position in inflammatory bowel disease. These results could support the company's revenue potential for its IBD portfolio.
From prnewswire.com
Who's involved
- AbbViePresented scientific abstracts regarding its inflammatory bowel disease portfolio.
- American College of GastroenterologyHosted the meeting where AbbVie presented its scientific abstracts.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
Could see increased revenue potential due to positive clinical data for SKYRIZI and RINVOQ.
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
American College of Gastroenterology
medical association of gastroenterologists